These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25345953)

  • 41. Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
    Suzuki L; Kanazawa A; Uzawa H; Osonoi Y; Masuyama A; Azuma K; Takeno K; Takayanagi N; Sato J; Someya Y; Komiya K; Goto H; Mita T; Ikeda F; Ogihara T; Shimizu T; Ohmura C; Saito M; Osonoi T; Watada H
    Expert Opin Pharmacother; 2017 Dec; 18(18):1921-1928. PubMed ID: 29141460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
    Dejager S; Razac S; Foley JE; Schweizer A
    Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.
    Mari A; Scherbaum WA; Nilsson PM; Lalanne G; Schweizer A; Dunning BE; Jauffret S; Foley JE
    J Clin Endocrinol Metab; 2008 Jan; 93(1):103-9. PubMed ID: 17925336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
    Melzer Cohen C; Davis C; Shalev V; Chodick G
    J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
    Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.
    Pratley RE; Schweizer A; Rosenstock J; Foley JE; Banerji MA; Pi-Sunyer FX; Mills D; Dejager S
    Diabetes Obes Metab; 2008 Sep; 10(10):931-8. PubMed ID: 18093207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug evaluation: vildagliptin-metformin single-tablet combination.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Feb; 26(2):138-54. PubMed ID: 19288260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes.
    Nakamura A; Terauchi Y
    Endocr J; 2013; 60(1):45-9. PubMed ID: 22972222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.
    Fonseca V; Baron M; Shao Q; Dejager S
    Horm Metab Res; 2008 Jun; 40(6):427-30. PubMed ID: 18401832
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy.
    Yoshioka K; Isotani H; Ohashi S; Imamura M
    Diabetes Metab Syndr; 2013; 7(1):32-4. PubMed ID: 23517793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
    Ristic S; Byiers S; Foley J; Holmes D
    Diabetes Obes Metab; 2005 Nov; 7(6):692-8. PubMed ID: 16219012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.